Real world challenges to communicating real-world evidence
Our recent series of blog posts examining the use of real-world evidence generated a great deal of interest and discussion about the potential to find new ways to improve patient health and manage the total cost of care. The first post in the series may be found here.
An article recently published by the National Pharmaceutical Council, “CER: Who Can Say What, and When Can They Say It?” offers an excellent summary of the communications issues pharmaceutical companies face in discussing both comparative effectiveness research and real-world evidence.
As noted by the article’s author, Robert W. Dubois, MD, PhD, Chief Science Officer for the NPC, “The challenges related to conducting, disseminating and communicating comparative effectiveness research won’t be solved overnight … but it is important to begin considering how these questions might be addressed.”
AstraZeneca believes it is important to be able engage in meaningful discussions about RWE study findings. To that end, we’ve formulated guidelines to allow specific AstraZeneca personnel to engage with payers and other stakeholders about RWE study findings in ways that are compliant from both a regulatory and legal perspective.
The NPC is planning to host a conference in early 2012 to explore these issues in greater detail and we look forward to learning how others in the health community are interested in engaging on RWE data and its applications.